Invivyd's pivotal COVID prevention trial pushes readout into Q3 2026
A sample-size increase in the BLA-directed DECLARATION trial added roughly 500 subjects and pushed Invivyd's topline guidance from mid-2026 to Q3, the only Phase 3 test of an antibody built to prevent COVID-19 before exposure.
Executive Summary
- Invivyd's pivotal antibody prevention trial is heading toward a delayed but still-on-track readout after a planned statistical adjustment added subjects to strengthen the study's power.
- A pre-specified interim check triggered an increase in trial size, which the company says improves confidence in detecting the drug's effect and pushed the expected data release later in the year.
- No other Phase 3 program is testing an antibody for prevention of symptomatic COVID-19 in this way, leaving the readout as the sole registrational test of this approach even as the broader field of antibody and vaccine programs against the same viral target has thinned over time.
- The data will determine whether the sponsor's pediatric follow-on study and BLA pathway, both already aligned with the FDA, move forward or stall.
The catalyst
DECLARATION (NCT07298434) is testing VYD2311, known as ibramvibart, against placebo for the pre-exposure prevention of symptomatic COVID-19, with the primary endpoint defined as RT-PCR-confirmed symptomatic COVID-19 through Day 90. Invivyd, Inc. disclosed on April 9, 2026 that a pre-specified, blinded sample-size re-estimation analysis, conducted after the first 1,500 of 1,818 enrolled subjects reached Day 45, triggered an increase of approximately 500 additional subjects. The company said the events accrued to that point already supported statistical power for the higher end of anticipated efficacy, and that the upsizing was designed to add robustness against variability in community COVID-19 attack rates. NCT07298434+1Study of VYD2311 for the Prevention of COVID-19NCT07298434Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and ...Apr 9, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The timing shift
Invivyd said the upsizing would likely shift topline results from its original mid-2026 guidance, defined as the second or third quarter, to the third quarter of 2026, a shift of about two months. That guidance has held steady across three separate disclosures dated April 9, May 14, and June 1, 2026, each pointing to the same July 1 to September 30 window. The trial's registry record shows one change to the primary completion date, from March 1, 2026 to August 1, 2026, recorded on May 15, 2026, alongside routine status toggles between Recruiting and Active, not recruiting as enrollment phases completed. No endpoint amendments and no primary-outcome changes after completion appear in that history, consistent with a trial whose design has stayed fixed while its enrollment size and calendar adjusted around a pre-planned statistical rule. Invivyd+1Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and ...Apr 9, 2026Study of VYD2311 for the Prevention of COVID-19NCT07298434
The regulatory posture
The FDA granted VYD2311 Fast Track designation for prevention of COVID-19 in individuals with underlying risk factors for severe disease in December 2025, and Invivyd said it aligned with the agency on an initial Pediatric Study Plan for a follow-on immunobridging and safety study, called DRUMMER, that will proceed only if DECLARATION succeeds. DECLARATION is designated as Invivyd's Biologics License Application-directed pivotal trial, meaning its result is the evidentiary basis the company plans to file on, not an exploratory study feeding a later pivotal program. Invivyd+1Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and ...Apr 9, 2026Study of VYD2311 for the Prevention of COVID-19NCT07298434
The competitive field
No other industry-sponsored Phase 3 trial is testing an antibody, or any modality, against the SARS-CoV-2 Spike Protein target specifically for pre-exposure prophylaxis of symptomatic COVID-19, making DECLARATION the only Phase 3 asset in this target-indication pairing. The nearest comparators by mechanism are Invivyd's own follow-on trial for the same antibody (NCT07655180) and earlier-phase programs against the same spike target, including Moderna's mRNA-1283 vaccine now in Phase 4 (NCT07089706), and Phase 1-2 vaccine and RNA-therapy candidates from smaller sponsors such as Vaxart (NCT06672055), CastleVax (NCT07215520), and CyanVac (NCT06742281). Field activity targeting the SARS-CoV-2 spike protein has declined sharply, with 23 recent trials against 270 older ones, a pattern consistent with a mechanism area that saw its clinical activity concentrate earlier in the pandemic and has since thinned.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.